GlassScriptPhysician profile
Sukhmani Singh
NPI 1366857922
$2,953.47
in general payments reported to CMS, 2019-2025
25 companies · $766 in 2025
The $766 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.90 · 2021: $316 · 2022: $588 · 2023: $810 · 2024: $417 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $422.22 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Novo Nordisk INC | $401.10 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $299.51 | 2021-2024 | Farxiga |
| Silk Road Medical, INC. | $215.08 | 2023-2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Tandem Diabetes Care, INC. | $164.40 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Lilly USA, LLC | $152.51 | 2021-2022 | |
| Cequr Corporation | $151.06 | 2023-2024 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $143.38 | 2025 | Yorvipath |
| Bayer Healthcare Pharmaceuticals INC. | $137.76 | 2023-2025 | |
| Emd Serono, INC. | $121.83 | 2023 | Mavenclad |
| Dexcom, INC. | $115.38 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $112.81 | 2023-2025 | Closurefast, Minimed 780g |
| Amgen INC. | $108.75 | 2025 | Tepezza |
| Horizon Therapeutics Plc | $85.91 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $61.67 | 2023 | Gore Excluder Aaa Endoprosthesis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $56.90 | 2019 | |
| Merck Sharp & Dohme LLC | $33.03 | 2021 | |
| Neurocrine Biosciences, INC. | $28.38 | 2025 | |
| Corcept Therapeutics | $23.61 | 2023 | Korlym |
| Novartis Pharmaceuticals Corporation | $22.11 | 2023 | |
| Abbvie INC. | $21.88 | 2025 | |
| Abbott Laboratories | $21.63 | 2024 | Freestyle Libre 3 |
| Kyowa Kirin, INC. | $20.19 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $17.90 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.47 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukhmani Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.